{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:19:12Z","timestamp":1791901152244,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jiac.2025.102823","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:18:07Z","timestamp":1759299487000},"page":"102823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical considerations of the safety and efficacy of clofazimine in the treatment of nontuberculous mycobacterial disease"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5272-2249","authenticated-orcid":false,"given":"Fumiya","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102823_bib1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.7326\/0003-4819-121-12-199412150-00001","article-title":"Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS clinical trials group protocol 157 study team","volume":"121","author":"Chaisson","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jiac.2025.102823_bib2","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1086\/514116","article-title":"A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California collaborative treatment group","volume":"176","author":"Dub\u00e9","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiac.2025.102823_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00002030-199703110-00008","article-title":"Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection","volume":"11","author":"Chaisson","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2025.102823_bib4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1128\/AAC.02615-15","article-title":"Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102823_bib5","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/AAC.01505-12","article-title":"In Vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease","volume":"56","author":"van Ingen","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102823_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102823_bib7","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1016\/j.xphs.2020.09.024","article-title":"Combining two antitubercular drugs, clofazimine and 4-aminosalicylic acid, in order to improve clofazimine aqueous solubility and 4-aminosalicylic acid thermal stability","volume":"109","author":"Bodart","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jiac.2025.102823_bib8","first-page":"107","article-title":"Tissue levels of clofazimine in a case of leprosy","volume":"47","author":"Desikan","year":"1976","journal-title":"Lepr Rev"},{"key":"10.1016\/j.jiac.2025.102823_bib9","first-page":"88","article-title":"Pulmonary clofazimine crystals in two patients with the acquired immunodeficiency syndrome","volume":"1","author":"Alfandari","year":"1997","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.jiac.2025.102823_bib10","first-page":"541","article-title":"Clofazimine crystals in alveolar macrophages from a patient with the acquired immunodeficiency syndrome","volume":"116","author":"Sandler","year":"1992","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jiac.2025.102823_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.5414\/CP203784","article-title":"Fatal course of clofazimine-induced pulmonary crystal deposition in a patient with melkersson\u2013rosenthal syndrome","volume":"58","author":"Wu","year":"2020","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2025.102823_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00000478-200001000-00016","article-title":"Clofazimine-induced crystal-storing histiocytosis producing chronic abdominal pain in a leprosy patient","volume":"24","author":"Sukpanichnant","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jiac.2025.102823_bib13","series-title":"Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 5e","author":"Rowland","year":"2020"},{"key":"10.1016\/j.jiac.2025.102823_bib14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/106002809102500513","article-title":"Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection","volume":"25","author":"Garrelts","year":"1991","journal-title":"DICP"},{"key":"10.1016\/j.jiac.2025.102823_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cdip.2006.05.002","article-title":"Drug-induced pathology in the large intestine","volume":"12","author":"Geboes","year":"2006","journal-title":"Curr Diagn Pathol"},{"key":"10.1016\/j.jiac.2025.102823_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/00313029309068897","article-title":"Severe abdominal pain in low dosage clofazimine","volume":"25","author":"Chong","year":"1993","journal-title":"Pathology"},{"key":"10.1016\/j.jiac.2025.102823_bib17","first-page":"208","article-title":"Acute abdomen in a patient treated with lamprene","volume":"60","author":"Jagadeesan","year":"1975","journal-title":"Int Surg"},{"key":"10.1016\/j.jiac.2025.102823_bib18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1067\/mpd.2001.111327","article-title":"Clofazimine enteropathy in a pediatric bone marrow transplant recipient","volume":"138","author":"Parizhskaya","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.jiac.2025.102823_bib19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1742-1241.1998.tb08900.x","article-title":"A case of clofazimine enteropathy","volume":"52","author":"Hameed","year":"1998","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jiac.2025.102823_bib20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0190-9622(86)80252-3","article-title":"Clofazimine enteropathy","volume":"15","author":"Venencie","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jiac.2025.102823_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/0253-7613.108323","article-title":"Clofazimine-induced enteropathy in a patient of leprosy","volume":"45","author":"Singh","year":"2013","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.jiac.2025.102823_bib22","first-page":"181","article-title":"Autopsy findings in a case of lepromatous leprosy treated with clofazimine","volume":"46","author":"Desikan","year":"1975","journal-title":"Lepr Rev"},{"key":"10.1016\/j.jiac.2025.102823_bib23","first-page":"328","article-title":"Small bowel deposition of crystals associated with the use of clofazimine (lamprene) in the treatment of prurigo nodularis","volume":"51","author":"Belaube","year":"1983","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"10.1016\/j.jiac.2025.102823_bib24","first-page":"221","article-title":"Radiological abnormalities of the ileum associated with the use of clofazimine (lamprene; B663) in the treatment of skin ulceration due to Mycobacterium ulcerans","volume":"51","author":"de Bergeyck","year":"1980","journal-title":"Lepr Rev"},{"issue":"2","key":"10.1016\/j.jiac.2025.102823_bib25","first-page":"105","article-title":"Long-term follow-up of clofazimine (lamprene) in the management of reactive phases of leprosy","volume":"46","author":"Karat","year":"1975","journal-title":"Lepr Rev"},{"key":"10.1016\/j.jiac.2025.102823_bib26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2133.1980.tb05697.x","article-title":"Splenic infarction and tissue accumulation of crystals associated with the use of clofazimine (Lamprene; B663) in the treatment of pyoderma gangrenosum","volume":"102","author":"McDougall","year":"1980","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jiac.2025.102823_bib27","first-page":"258","article-title":"Unnecessary laparotomy for abdominal pain and fever due to clofazimine","volume":"50","author":"Bryceson","year":"1979","journal-title":"Lepr Rev"},{"key":"10.1016\/j.jiac.2025.102823_bib28","first-page":"119","article-title":"Evaluation of B.663 in human leprosy","volume":"35","author":"Atkinson","year":"1967","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"10.1016\/j.jiac.2025.102823_bib29","first-page":"175","article-title":"Clofazimine and eosinophilic enteritis","volume":"48","author":"Mason","year":"1977","journal-title":"Lepr Rev"},{"key":"10.1016\/j.jiac.2025.102823_bib30","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3390\/pharmaceutics16121545","article-title":"Effects of different weak small organic acids on clofazimine solubility in aqueous media","volume":"16","author":"Topalovi\u0107","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jiac.2025.102823_bib31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0090-9556(25)06563-8","article-title":"Metabolism of clofazimine in leprosy patients","volume":"9","author":"Feng","year":"1981","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jiac.2025.102823_bib32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0090-9556(25)07882-1","article-title":"A new urinary metabolite of clofazimine in leprosy patients","volume":"10","author":"Feng","year":"1982","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jiac.2025.102823_bib33","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.02278-13","article-title":"Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein","volume":"58","author":"Horita","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102823_bib34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jiac.2025.102823_bib35","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1093\/jac\/dkaa310","article-title":"Clofazimine pharmacokinetics in patients with TB: dosing implications","volume":"75","author":"Abdelwahab","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102823_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107718","article-title":"Clofazimine serum concentration and safety\/efficacy in nontuberculous mycobacterial pulmonary disease treatment","volume":"231","author":"Watanabe","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.jiac.2025.102823_bib37","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/jac\/dkae309","article-title":"A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease","volume":"79","author":"Stemkens","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102823_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00794-23","article-title":"Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis","volume":"68","author":"Ali","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102823_bib39","doi-asserted-by":"crossref","first-page":"e873","DOI":"10.1093\/infdis\/jiaf057","article-title":"Pharmacokinetics and safety of clofazimine in children with rifampicin-resistant tuberculosis","volume":"231","author":"Hughes","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiac.2025.102823_bib40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00007691-200502000-00005","article-title":"Evaluation of Bayesian estimation of pharmacokinetic parameters","volume":"27","author":"Tsuchiwata","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2025.102823_bib41","doi-asserted-by":"crossref","first-page":"10276","DOI":"10.1074\/jbc.M110.200501","article-title":"Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species","volume":"286","author":"Yano","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jiac.2025.102823_bib42","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/jac\/dkh114","article-title":"Anti-staphylococcal activity and mode of action of clofazimine","volume":"53","author":"Oliva","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102823_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02052-16","article-title":"Clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease","volume":"61","author":"Yang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102823_bib44","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term Follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine And\/Or rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2025.102823_bib45","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.chest.2023.11.038","article-title":"Safety and efficacy of clofazimine as an alternative for rifampicin in Mycobacterium avium complex pulmonary disease treatment: outcomes of a randomized trial","volume":"165","author":"Zweijpfenning","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2025.102823_bib46","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00234-24","article-title":"Low azithromycin maximal concentrations in patients concomitantly taking rifampicin: time to move away from rifampicin in the treatment of non-tuberculous mycobacteria?","volume":"68","author":"Gaviraghi","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102823_bib47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","article-title":"Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study","volume":"11","author":"Miwa","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jiac.2025.102823_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106025","article-title":"Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy","volume":"169","author":"Ito","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.jiac.2025.102823_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01157-23","article-title":"Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model","volume":"68","author":"Salillas","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102823_bib50","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.chest.2020.07.040","article-title":"Minimal inhibitory concentration of clofazimine among clinical isolates of nontuberculous mycobacteria and its impact on treatment outcome","volume":"159","author":"Kwak","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2025.102823_bib51","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.3390\/jcm10194581","article-title":"In vitro activity and clinical outcomes of clofazimine for nontuberculous mycobacteria pulmonary disease","volume":"10","author":"Kim","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jiac.2025.102823_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107061","article-title":"Efficacy of clofazimine-containing regimens for treatment of Mycobacterium avium complex-pulmonary disease in patients unsuitable for standard treatment regimen","volume":"63","author":"Bao","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2025.102823_bib53","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jid.2017.09.031","article-title":"The physicochemical basis of clofazimine-induced skin pigmentation","volume":"138","author":"Murashov","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jiac.2025.102823_bib54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.11604\/pamj.2022.42.14.34956","article-title":"Clofazimine induced pigmentation in leprosy patches","volume":"42","author":"Chavhan","year":"2022","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.jiac.2025.102823_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2024.06.004","article-title":"Changes in skin discoloration according to clofazimine dosage in nontuberculous mycobacterial pulmonary disease","volume":"31","author":"Kurahara","year":"2025","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102823_bib56","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2169\/internalmedicine.4498-24","article-title":"Quantifying the reversibility of clofazimine-induced pigmentation in a patient with Mycobacterium abscessus pulmonary disease","volume":"64","author":"Ito","year":"2025","journal-title":"Intern Med"},{"key":"10.1016\/j.jiac.2025.102823_bib57","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1113\/JP270526","article-title":"Predicting drug-induced QT prolongation and torsades de pointes","volume":"594","author":"Roden","year":"2016","journal-title":"J Physiol"},{"key":"10.1016\/j.jiac.2025.102823_bib58","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02687-20","article-title":"Effect of clofazimine concentration on QT prolongation in patients treated for tuberculosis","volume":"65","author":"Abdelwahab","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102823_bib59","article-title":"Effects of bedaquiline combined with fluoroquinolone and\/or clofazimine on QT interval in patients with multidrug-resistant tuberculosis: a retrospective study","volume":"11","author":"Li","year":"2023","journal-title":"Microbiol Spectr"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2500220X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2500220X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:35:56Z","timestamp":1761827756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X2500220X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1341321X2500220X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102823","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical considerations of the safety and efficacy of clofazimine in the treatment of nontuberculous mycobacterial disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102823","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102823"}}